<DOC>
	<DOCNO>NCT00596817</DOCNO>
	<brief_summary>This study evaluate efficacy Vortioxetine prevention relapse major depressive episode patient respond open-label treatment Vortioxetine .</brief_summary>
	<brief_title>Efficacy Vortioxetine ( Lu AA21004 ) Prevention Relapse Major Depressive Episodes</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Major Depressive Episode ( MDE ) primary diagnosis accord DSMIV TR criterion At least one MDE current one Moderate severe depression Any current psychiatric disorder Major Depressive Disorder ( MDD ) define DSMIV TR Any substance disorder within previous 6 month Female patient childbearing potential use effective contraception Use psychoactive medication 2 week prior screen study Randomisation Criteria : Patients remission ( MADRS total score &lt; =10 ) Week 10 Week 12 Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Relapse prevention</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Multicentre study</keyword>
</DOC>